Innovative funding models like value-based payments can change providers’ incentives and drive them to seek solutions like palliative care, said Allison Silvers, vice president of payment and policy at the Center to Advance Palliative Care.
Innovative funding models like value-based payments can change providers’ incentives and drive them to seek solutions like palliative care, said Allison Silvers, vice president of payment and policy at the Center to Advance Palliative Care.
Transcript (slightly modified)
How can innovative funding models drive transformation in organization operations?
I think there’s 2 parts to that. The first is innovative funding changes the incentives that providers operate under. Using that example of COPD [chronic obstructive pulmonary disease], pulmonologists might be driven to produce certain outcomes and certain costs within a framework that they wouldn’t have otherwise been responsible for. So they’re going to be looking for solutions, and that’s where innovative funding really helps palliative care, because palliative care is an important solution to what they’re trying to achieve.
Innovative funding as value funding—making sure that costs are within targets and making sure that patient experience is within certain, I would think very high, parameters; certain quality metrics are achieved—all of that can be helped with palliative care. So it maybe is even not so much how you pay for the palliative care, but how you pay the treating providers could drive a demand for palliative care integration.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
Interstitial Lung Abnormalities in Patients With COPD Linked to Cancer, Heart Failure Risks
October 23rd 2024Interstitial lung abnormalities (ILAs) in patients with chronic obstructive pulmonary disease (COPD) are linked to lower lung adenocarcinoma rates but higher rates of other cancers and heart failure.
Read More